Market News / Story
New results across pediatric, adult and real-world insomnia settings highlight the expanding clinical evidence for daridorexant at Sleep Europe 2026
GlobeNewswire ·
GlobeNewswire reports: Phase 2 results with daridorexant in pediatric insomnia disorder will be presented in a late-breaking "Impactful Clinical Trial" session. These are the first and only investigational data of a dual orexin receptor antagonist in children. A growing body of real-world evidence will examine the use of daridorexant in routine clinical practice, including sleep outcomes, daytime functioning, quality of life and work productivity. Further research will examine daridorexant…



